Full Press Release Details
to Announce Second Quarter 2017 Results on August 9th, 2017
24, 2017 -- Xtant Medical Holdings, Inc. (NYSE MKT: XTNT), a leader in the development of regenerative medicine products and medical
devices, today announced that it will release its financial results for the second quarter ended June 30, 2017, after the close
of the financial markets on Wednesday, August 9, 2017.
conference call will be conducted by Carl O'Connell, Chief Executive Officer and President, and John Gandolfo, Chief Financial
Officer, to review the results. The call will be held at 10:00 AM ET, on Thursday, August 10, 2017. Please refer to the information
below for conference call dial-in information and webcast registration.
Conference Date: Thursday, August 10, 2017 10:00 AM ET
Conference dial-in: 877-269-7756
International dial-in: 201-689-7817
Conference Call Name: Xtant Medical Holdings, Inc. Second Quarter 2017 Results Call
Webcast Registration: Click Here
Following the live call, a replay will be available on the Company's website, www.xtantmedical.com,
under "Investor Info".
Xtant Medical develops, manufactures and markets regenerative medicine products and medical devices for domestic and international
markets. Xtant Medical products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for
the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment
of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. With core competencies
in both biologic and non-biologic surgical technologies, Xtant Medical can leverage its resources to successfully compete in global
neurological and orthopedic surgery markets. For further information, please visit www.xtantmedical.com.
Regarding Forward-looking Statements
This press release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include
statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such
as "continue," "efforts," "expects," "anticipates," "intends," "plans,"
"believes," "estimates," "projects," "forecasts," "strategy," "will,"
"goal," "target," "prospects," "potential," "optimistic," "confident,"
"likely," "probable" or similar expressions or the negative thereof.
Statements of historical
fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties,
and actual results may differ materially depending on a variety of important factors, including, among others: the ability to comply
with covenants in the Company's senior credit facility and to make deferred interest payments; the ability to maintain sufficient
liquidity to fund operations; the ability to remain listed on the NYSE MKT; the ability to obtain financing on reasonable terms;
the ability to increase revenue; the ability to continue as a going concern; the ability to maintain sufficient liquidity to fund
operations; the ability to achieve expected results; the ability to remain competitive; government regulations; the ability to
innovate and develop new products; the ability to obtain donor cadavers for products; the ability to engage and retain qualified
technical personnel and members of the Company's management team; the availability of Company facilities; government and
third-party coverage and reimbursement for Company products; the ability to obtain regulatory approvals; the ability to successfully
integrate recent and future business combinations or acquisitions; the ability to use net operating loss carry-forwards to offset
future taxable income; the ability to deduct all or a portion of the interest payments on the notes for U.S. federal income tax
purposes; the ability to service Company debt; product liability claims and other litigation to which we may be subjected; product
recalls and defects; timing and results of clinical studies; the ability to obtain and protect Company intellectual property and
proprietary rights; infringement and ownership of intellectual property; the ability to remain accredited with the American Association
of Tissue Banks; influence by Company management; the ability to pay dividends; and the ability to issue preferred stock; and other
factors are listed in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q under the heading "Risk
Factors." You should carefully consider the trends, risks and uncertainties described in this document, the Form 10-K and
other reports filed with or furnished to the SEC before making any investment decision with respect to our securities. If any of
these trends, risks or uncertainties actually occurs or continues, our business, financial condition or operating results could
be materially adversely affected, the trading prices of our securities could decline, and you could lose all or part of your investment.
The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements
attributable to us or persons acting on our behalf are expressly qualified in their entirety by this cautionary statement.